Cargando…
Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
Migraine is a very disabling disorder with severe impact on patients’ lives and substantive costs to society in terms of healthcare costs and lost productivity. Prevention is a key component of migraine therapy, and while numerous preventive options exist, each is burdened by either troublesome side...
Autores principales: | Tso, Amy R., Goadsby, Peter J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486583/ https://www.ncbi.nlm.nih.gov/pubmed/28653227 http://dx.doi.org/10.1007/s11940-017-0463-4 |
Ejemplares similares
-
Treatment of Headache in the Elderly
por: Hershey, Linda A., et al.
Publicado: (2012) -
It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine
por: Kubota, Gabriel Taricani
Publicado: (2022) -
Why are CGRP monoclonal antibodies not yet the first line treatment in migraine prevention?
por: Simioni, Caio Vinicius de Meira Grava
Publicado: (2022) -
Acute Migraine Therapy: New Drugs and New Approaches
por: Monteith, Teshamae S., et al.
Publicado: (2010) -
Basic Considerations for the Use of Monoclonal Antibodies in Migraine
por: Levin, Morris, et al.
Publicado: (2018)